OM:ISOFOL

Stock Analysis Report

Executive Summary

Isofol Medical AB (publ), a clinical stage company, develops, manufactures, and sells folate-based therapies in Sweden and inetrnationally.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Risks

  • Isofol Medical has significant price volatility in the past 3 months.

Share Price & News

How has Isofol Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-14.3%

OM:ISOFOL

-3.0%

SE Biotechs

-1.2%

SE Market


1 Year Return

-8.1%

OM:ISOFOL

-19.7%

SE Biotechs

-2.6%

SE Market

ISOFOL outperformed the Biotechs industry which returned -19.7% over the past year.

ISOFOL underperformed the Market in Sweden which returned -2.6% over the past year.


Share holder returns

ISOFOLIndustryMarket
7 Day-14.3%-3.0%-1.2%
30 Day-19.4%-10.2%-4.8%
90 Day-5.4%-2.6%-1.8%
1 Year-8.1%-8.1%-19.4%-19.7%1.5%-2.6%
3 Yearn/a41.8%30.9%24.4%6.0%
5 Yearn/a52.2%50.9%44.9%14.3%

Price Volatility Vs. Market

How volatile is Isofol Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Isofol Medical undervalued based on future cash flows and its price relative to the stock market?

3.05x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Isofol Medical to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Isofol Medical to establish if it is available at substantial discount.


Price Based on Earnings

Isofol Medical is loss making, we can't compare its value to the SE Biotechs industry average.

Isofol Medical is loss making, we can't compare the value of its earnings to the Sweden market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Isofol Medical, we can't assess if its growth is good value.


Price Based on Value of Assets

Isofol Medical is good value based on assets compared to the SE Biotechs industry average.


Next Steps

Future Growth

How is Isofol Medical expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

-17.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Isofol Medical's revenue is expected to grow significantly at over 20% yearly.

Isofol Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.

Isofol Medical's revenue growth is expected to exceed the Sweden market average.

Unable to compare Isofol Medical's earnings growth to the Sweden market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Isofol Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Isofol Medical will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Isofol Medical performed over the past 5 years?

-18.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Isofol Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Isofol Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Isofol Medical's 1-year growth to the SE Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Isofol Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Isofol Medical has efficiently used its assets last year compared to the SE Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Isofol Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Isofol Medical's financial position?


Financial Position Analysis

Isofol Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Isofol Medical's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Isofol Medical has no debt.

Isofol Medical has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

Isofol Medical has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Isofol Medical has sufficient cash runway for 2.6 years based on current free cash flow.

Isofol Medical has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 37.7% each year.


Next Steps

Dividend

What is Isofol Medical's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Isofol Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Isofol Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Isofol Medical has not reported any payouts.

Unable to verify if Isofol Medical's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Isofol Medical has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Isofol Medical's dividends in 3 years as they are not expected to pay a notable one for Sweden.


Next Steps

Management

What is the CEO of Isofol Medical's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average management tenure


CEO

Anders Rabbe (49yo)

0.0yrs

Tenure

kr2,717,876

Compensation

Mr. Anders Rabbe serves as Chief Executive Officer of Isofol Medical AB. Mr. Rabbe has broad experience from investment operations and acquisitions as well as leading positions within entrepreneurial growt ...


CEO Compensation Analysis

Anders's remuneration is higher than average for companies of similar size in Sweden.

Anders's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.8yrs

Average Tenure

The average tenure for the Isofol Medical management team is less than 2 years, this suggests a new team.


Board Age and Tenure

0.8yrs

Average Tenure

58yo

Average Age

The average tenure for the Isofol Medical board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

Buykr405,00003 Sep 18
Anders Rabbe
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares15,000
Max Pricekr27.00

Ownership Breakdown


Management Team

  • Anders Rabbe (49yo)

    Chief Executive Officer

    • Tenure: 0.0yrs
    • Compensation: kr2.72m
  • Sven Erickson

    Chief Commercial Officer

    • Tenure: 2.0yrs
  • Gustaf Albèrt

    Chief Financial Officer

    • Tenure: 1.8yrs
  • Roger Tell

    Chief Medical Officer

    • Tenure: 0.5yrs

Board Members

  • Anna Belfrage (57yo)

    Director

    • Tenure: 0.2yrs
  • Alain Herrera (69yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: kr232.00k
  • Paula S. Boultbee (61yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: kr50.00k
  • Jarl Jungnelius (68yo)

    Chairman of the Board

    • Tenure: 0.8yrs
    • Compensation: kr686.00k
  • Magnus Björsne (55yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: kr50.00k
  • Robert Marchesani (58yo)

    Director

    • Tenure: 0.2yrs
  • Pär-Ola Mannefred (58yo)

    Director

    • Tenure: 0.2yrs

Company Information

Isofol Medical AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Isofol Medical AB (publ)
  • Ticker: ISOFOL
  • Exchange: OM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr730.849m
  • Shares outstanding: 32.05m
  • Website: https://isofolmedical.com

Location

  • Isofol Medical AB (publ)
  • Biotech Center
  • Arvid Wallgrens Backe 20
  • Gothenburg
  • Västra Götaland County
  • 413 46
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ISOFOLOM (OMX Nordic Exchange Stockholm)YesOrdinary SharesSESEKApr 2017

Biography

Isofol Medical AB (publ), a clinical stage company, develops, manufactures, and sells folate-based therapies in Sweden and inetrnationally. Its clinical lead candidate is Modufolin, a novel folate-based th ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/18 21:51
End of Day Share Price2019/08/16 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.